Exchange: NASDAQ·Updated 12:00 AM EST

MURA Mural Oncology plc

$2.04
$0.0003
(0.01%)
Pre-Market
Prev Close $2.04
Mkt Cap$35.38M
Vol127,775.00

About MURA

Mural Oncology Plc is a clinical-stage oncology company, which focuses on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. Its lead product candidate is the Nemvaleukin Alfa which is an interleukin-2 cytokine designed to capture and expand therapeutic benefits of high-dose recombinant human IL-2. The company was founded on May 31, 2017 and is headquartered in Dublin, Ireland.
53

Neutral Sentiment

How do you feel about MURA?

Advertisement|Remove ads.